Day: October 13, 2023

TORONTO, ONTARIO, Oct. 13, 2023 (GLOBE NEWSWIRE) — (“Amaroq,” “Company” or the “Corporation”) Senior Management Appointments and Conditional RSU Awards TORONTO, ONTARIO – October 13, 2023 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mine development corporation with a substantial land package of gold and strategic mineral assets across in Southern Greenland, is pleased to provide an update on senior management appointments. Appointment of Executive Vice President Joan Plant has been appointed Executive Vice President. Joan has 13 years of experience operating in Greenland, and has worked on the Nalunaq project since 2010. During this time, she has built a strong relationship with the Government of Greenland whilst successfully applying her in-depth knowledge and expertise covering all aspects of the...

LOS ANGELES, Oct. 13, 2023 (GLOBE NEWSWIRE) — Versus Systems Inc. (“Versus” or the “Company”) (NASDAQ: VS), today announced the pricing of its reasonable best efforts public offering of 13,043,490 of its common shares (or common share equivalents in lieu thereof) and accompanying warrants to purchase up to an aggregate of 13,043,490 common shares at a combined public offering price of $0.23 per share and accompanying warrant, resulting in gross proceeds of approximately $3.0 million. The warrants have an exercise price of $0.23 per share, are immediately exercisable upon issuance and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about October 17, 2023, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the...

 Clinical dose escalation data for RMC-6236, a RASMULTI(ON) Inhibitor, show oral bioavailability, well-tolerated safety profile and preliminary evidence of anti-tumor activity across multiple RAS mutations First clinical data presentation for RMC-6291, a RASG12C(ON) Inhibitor, highlights encouraging initial tolerability, safety and differentiated anti-tumor activity Investor webcast to be held Sunday, October 22 at 12:30pm Eastern Time REDWOOD CITY, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced encouraging preliminary clinical data for RMC-6236, its RASMULTI(ON) Inhibitor, and RMC-6291, its RASG12C(ON) Inhibitor, from the respective Phase 1/1b studies. These data were presented during the...

ROBIT PLC         STOCK EXCHANGE RELEASE         13 OCTOBER 2023 AT 18.45 EEST        ROBIT PLC: REPURCHASE OF OWN SHARES 13 OCTOBER 2023Robit Plc  Nasdaq Helsinki Ltd  Date 13.10.2023Exchange transaction BUYShare trading code ROBITAmount, shares 1693Average price / share, EUR 1,429690Total cost, EUR 2420,46Robit Plc now holds a total of 51 873 shares including the shares repurchased on 13 October 2023. Detailed information concerning the repurchase is attached to this stock exchange release. On behalf of Robit Plc OP Corporate Bank Lasse Jaakonmäki Further information:Robit PlcArto Halonen, Group CEO+358 40 028 0717arto.halonen@robitgroup.com Distribution:Nasdaq Helsinki LtdKey mediawww.robitgroup.com Robit is the specialist focused on high quality drilling consumables for the mining and construction markets...

Oma Savings Bank Plc Stock Exchange Release 13.10.2023          Oma Savings Bank Plc: Acquisition of own shares 13.10.2023     In the NASDAQ OMX Helsinki         Trade date 13.10.2023  Bourse trade Buy  Share OMASP  Amount 2,202 SharesAverage price/ share 20.9291 EURTotal cost 46,085.88 EUR          Company now holds a total of 128 488 shares  including the shares repurchased on 13.10.2023            On behalf of Oma Savings Bank Plc       Nordea Bank Finland Plc         Janne Sarvikivi Sami Huttunen            For further information, please contact:  Sarianna Liiri    CFO    Tel. +358 40 835 6712    sarianna.liiri@omasp.fi         Minna Sillanpää    CCO    Tel. +358 50 66592    minna.sillanpaa@omasp.fi         www.omasp.fi...

NEW YORK, Oct. 13, 2023 (GLOBE NEWSWIRE) — Carlyle Secured Lending, Inc. (“Carlyle Secured Lending”) (NASDAQ: CGBD) will host a conference call at 10:00 a.m. EDT on Wednesday, November 8, 2023 to announce its third quarter 2023 financial results. A news release containing the quarterly results will be issued after market close on Tuesday, November 7, 2023. The conference call will be available via public webcast via a link on Carlyle Secured Lending’s website at carlylesecuredlending.com and will also be available on the website soon after the call’s completion. About Carlyle Secured Lending, Inc.     Carlyle Secured Lending, Inc. is a publicly traded (NASDAQ: CGBD) business development company (“BDC”) which began investing in 2013. Carlyle Secured Lending focuses on providing directly originated, financing solutions across the...

SANTIAGO, Chile, Oct. 13, 2023 (GLOBE NEWSWIRE) — You are cordially invited to participate in Banco Santander Chile’s (NYSE: BSAC) conference call-webcast on Friday, November 3, 2023, at 10.00 AM (New York Time) where we will discuss 3Q 2023 financial results. The Bank’s Officers participating in the conference call are: Emiliano Muratore, CFO, Cristian Vicuña, Chief Strategy Officer & Head of IR and Carmen Gloria Silva, Economist. A question and answer session will follow the presentation. The Management Commentary report will be published on October 31, 2023, before the market opens. The quiet period begins on October 17. To participate, the webcast presentation can be viewed at: https://mm.closir.com/slides?id=720987 Or please dial in using any of the below numbers: United Kingdom+44 203 984 9844 USA+1 718 866...

The opinion was based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and extensive nonclinical development program.2,3 If approved by the European Medicines Agency, rezafungin could be the first new treatment option in over 10 years for patients with invasive candidiasis.4SAN DIEGO and CAMBRIDGE, England, Oct. 13, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, and Mundipharma today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for rezafungin...